UFP TECHNOLOGIES INC UFPT
The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The Company is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. Our single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.
The consolidated financial statements of the Company include the accounts and results of operations of UFP Technologies, Inc. and its wholly owned subsidiaries, as well as its share of minority-owned equity investments. All significant intercompany balances and transactions have been eliminated in consolidation.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $602.8M | $504.4M | $400.1M | $353.8M | $206.3M | $179.4M | $198.4M | $190.5M | $147.8M | $146.1M |
| Cost of revenue | $432.4M | $357.7M | $287.8M | $263.5M | $155.2M | $134.7M | $144.4M | $142.1M | $112.4M | $111.5M |
| Gross profit | $170.4M | $146.7M | $112.2M | $90.3M | $51.1M | $44.7M | $54.0M | $48.3M | $35.5M | $34.6M |
| R&D | $8.6M | $10.4M | $7.2M | $9.3M | $8.5M | $8.2M | $8.8M | $10.5M | $5.0M | $1.3M |
| SG&A | $77.4M | $62.2M | $50.9M | $45.8M | $29.5M | $27.5M | $29.3M | $27.7M | $23.7M | $24.1M |
| Operating income | $92.3M | $80.9M | $57.7M | $55.4M | $21.2M | $16.7M | $24.7M | $19.6M | $11.7M | $12.2M |
| Interest expense | $9.8M | $8.1M | $3.6M | $2.8M | $39.0K | $83.0K | $674.0K | $1.3M | $50.0K | $69.0K |
| Pre-tax income | $82.5M | $73.0M | $53.9M | $52.7M | $21.2M | $16.3M | $23.6M | $18.4M | $11.9M | $12.3M |
| Income tax | $14.2M | $14.0M | $9.0M | $10.9M | $5.3M | $2.9M | $3.9M | $4.1M | $2.6M | $4.3M |
| Net income | $68.3M | $59.0M | $44.9M | $41.8M | $15.9M | $13.4M | $19.8M | $14.3M | $9.2M | $8.0M |
| EPS, basic | 8.87 | 7.69 | 5.89 | 5.52 | 2.11 | 1.79 | 2.66 | 1.95 | 1.27 | 1.11 |
| EPS, diluted | 8.75 | 7.58 | 5.83 | 5.45 | 2.09 | 1.77 | 2.63 | 1.93 | 1.26 | 1.10 |
| Shares, diluted (wtd. avg.) | $7.8M | $7.8M | $7.7M | $7.7M | $7.6M | $7.6M | $7.5M | $7.4M | $7.3M | $7.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.3M | $13.4M | $5.3M | $4.5M | $11.1M | $24.2M | $3.7M | $3.2M | $38.0M | $31.4M |
| Receivables | $82.9M | $84.7M | $64.4M | $55.1M | $39.4M | $26.4M | $28.6M | $28.3M | $21.4M | $21.2M |
| Inventory | $86.9M | $87.5M | $70.2M | $53.5M | $33.4M | $18.6M | $18.3M | $19.6M | $12.9M | $14.2M |
| Total current assets | $201.0M | $194.9M | $144.6M | $116.3M | $87.3M | $71.9M | $53.2M | $55.6M | $75.1M | $69.8M |
| Property, plant and equipment | $79.1M | $70.6M | $62.1M | $58.1M | $56.6M | $53.8M | $56.7M | $57.7M | $53.7M | $48.5M |
| Goodwill | $197.4M | $189.7M | $113.3M | $113.0M | $107.9M | $51.8M | $51.8M | $51.8M | $7.3M | $7.3M |
| Other intangibles | $140.8M | $144.3M | $64.1M | $68.4M | $67.6M | $19.7M | $21.0M | $22.2M | — | $318.0K |
| Total assets | $655.1M | $629.0M | $404.1M | $378.2M | $334.1M | $203.2M | $188.8M | $189.6M | $138.2M | $127.9M |
| Accounts payable | $24.3M | $24.3M | $22.3M | $20.0M | $10.6M | $4.1M | $4.6M | $6.8M | $4.2M | $4.0M |
| Short-term debt | $12.5M | $12.5M | $4.0M | $4.0M | $4.0M | $0 | — | $2.9M | — | $856.0K |
| Total current liabilities | $74.9M | $76.3M | $58.2M | $56.0M | $38.8M | $15.1M | $16.8M | $20.7M | $9.9M | $9.6M |
| Long-term debt | $123.0M | $176.9M | $28.0M | $51.0M | $71.0M | $0 | — | $22.3M | — | $856.0K |
| Total liabilities | $231.2M | $286.2M | $118.0M | $140.6M | $139.7M | $26.3M | $26.8M | $49.1M | $14.5M | $14.9M |
| Retained earnings | $374.8M | $306.5M | $247.5M | $202.6M | $160.8M | $144.9M | $131.6M | $111.8M | $97.6M | $88.4M |
| Total equity | $423.9M | $342.8M | $286.1M | $237.5M | $194.4M | $176.9M | $162.0M | $140.5M | $123.7M | $113.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $91.9M | $66.6M | $41.3M | $17.7M | $14.3M | $25.0M | $31.2M | $21.3M | $17.5M | $9.3M |
| Depreciation and amortisation | $19.1M | $14.7M | $11.4M | $11.9M | $8.4M | $8.3M | $8.2M | $7.8M | $5.6M | $5.6M |
| Stock-based compensation | $8.9M | $6.8M | $4.6M | $3.2M | $2.4M | $1.8M | $1.6M | $1.2M | $1.1M | $1.1M |
| Capital expenditure | — | $9.7M | $10.5M | $13.8M | $5.4M | $4.4M | $5.8M | $5.4M | $10.4M | $7.2M |
| Investing cash flow | -$27.6M | -$210.2M | -$10.5M | $1.3M | -$101.5M | -$4.3M | -$5.8M | -$82.3M | -$10.4M | -$7.2M |
| Financing cash flow | -$58.2M | $152.4M | -$30.0M | -$25.9M | $74.0M | -$285.0K | -$24.9M | $26.3M | -$475.0K | -$559.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028710.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |